Biopharma markets closed the first half of 2023 with renewed optimism and an encouraging outlook for the rest of the year. That comes as major market indices have trended upward—with biopharma emerging as the most heavily weighted sector in the Russell 2000—despite macro concerns following the regional banking crisis.
Public financing markets have warmed, but private companies continue to face challenging decisions amid a slow IPO market and selective private financing market. Simultaneously, SMID-cap M&A helped recycle capital in the sector.
William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q2 2023 U.S. Biopharma Recap.
Complete the form below to download your copy of the report.